Huang, Samuel
Siah, Kien Wei http://orcid.org/0000-0002-7837-7030
Vasileva, Detelina
Chen, Shirley
Nelsen, Lita
Lo, Andrew W. http://orcid.org/0000-0003-2944-7773
Funding for this research was provided by:
The MIT Laboratory for Financial Engineering is a research center at MIT supported by both government and private-sector organizations. See https://lfe.mit.edu/ for more information.
Article History
Received: 28 April 2019
Accepted: 3 February 2021
First Online: 10 March 2021
Competing interests
: All authors were affiliated with MIT during the course of this project. L.N. was head of MIT’s Technology Licensing Office at the start of the project, and currently consults for biopharma companies and investors. A.W.L. reports personal investments in private and public biotech companies, biotech venture capital funds, and life sciences mutual funds, and is a cofounder and partner of QLS Advisors, a healthcare analytics company; an advisor to BrightEdge Ventures; a director of Roivant Sciences Ltd, BridgeBio Pharma and Annual Reviews; chairman emeritus and senior advisor to the AlphaSimplex Group; and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH’s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board.